DUBLIN--(BUSINESS WIRE)--Jan 11, 2023--

The “LAMEA Attention Deficit Hyperactivity Disorder Market Size, Share & Industry Trends Analysis Report By Drug Type, By Demographics (Adults and Children), By Distribution Channel (Retail Pharmacy and Hospital Pharmacy), By Country and Growth Forecast, 2022 - 2028” report has been added to ResearchAndMarkets.com’s offering.

The Latin America, Middle East and Africa Attention Deficit Hyperactivity Disorder Market should witness market growth of 7.3% CAGR during the forecast period (2022-2028).

As novel treatments are released, it will be crucial to assess their cost-effectiveness to give clinicians, third-party payers, patients, and families an idea of their potential worth. In the near future, the market expansion is anticipated to be driven by extensive research studies carried out by organizations to assess the safety and efficacy of medications in patients with ADHD. Positive findings from these investigations create new business prospects.

For example, alpha-2-adrenergic agonists like guanfacine & clonidine, according to a Boston Children’s Hospital study from 2021, can be helpful in reducing illness symptoms in children.

Additionally, it is shown that these drugs have fewer adverse side effects than other stimulants such as amphetamines (Adderall, Vyvanse), methylphenidate (Ritalin, Concerta), and caffeine, which are frequently used as initial treatments for the disorder. Therefore, the expansion of essential players’ efforts to promote their products is creating new economic opportunities.

Several studies have established a high variation in the prevalence of ADHD in Brazil. Nearly 65% of diagnosed children with ADHD have also continued to show the symptoms of the disorder well into adulthood. This further suggested that ADHD can be regarded as a chronic developmental disorder in the nation. Similarly, in the Middle East region, the prevalence of ADHD was assessed based on the DSM-IV guidelines in Egypt, Palestine, Saudi Arabia, Tunisia, Oman, Qatar, Lebanon, Tunisia, and Iraq.

The Brazil market dominated the LAMEA Attention Deficit Hyperactivity Disorder Market by Country in 2021; thereby, achieving a market value of $199.4 million by 2028. The Argentina market is showcasing a CAGR of 7.9% during (2022-2028). Additionally, The UAE market would register a CAGR of 7% during (2022-2028).

Scope of the Study

By Drug Type

• Stimulants
  • Amphetamine
  • Methylphenidate
  • Lisdexamfetamine
  • Dexmethylphenidate
• Non-stimulants
  • Atomoxetine
  • Guanfacine
  • Clonidine
  • Others

By Demographics

• Adults
• Children

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• Eli Lilly And Company
• Pfizer, Inc. (Global Blood Therapeutics, Inc.)
• Johnson & Johnson (Johnson & Johnson Services, Inc.)
• Lupin Limited
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Mallinckrodt PLC
• Purdue Pharma L.P.
• Aytu BioPharma, Inc.
• Supernus Pharmaceuticals, Inc.

Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview

Chapter 3. Strategies deployed in Attention Deficit Hyperactivity Disorder Market

Chapter 4. LAMEA Attention Deficit Hyperactivity Disorder Market by Drug Type

Chapter 5. LAMEA Attention Deficit Hyperactivity Disorder Market by Demographics

Chapter 6. LAMEA Attention Deficit Hyperactivity Disorder Market by Distribution Channel

Chapter 7. LAMEA Attention Deficit Hyperactivity Disorder Market by Country

Chapter 8. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/8v8acy

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com:https://www.businesswire.com/news/home/20230111005666/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD: AFRICA LATIN AMERICA MIDDLE EAST

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2023.

PUB: 01/11/2023 10:12 AM/DISC: 01/11/2023 10:12 AM

http://www.businesswire.com/news/home/20230111005666/en